Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 17/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | HCN1 | O60741 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4369949 | 0.93 | SLC6A9 (0.60) | SLC6A9CYP2C9HCN1OPRM1CNR1 | |
| SCHEMBL4364813 | 0.80 | SLC6A9 (0.66) | SLC6A9CYP2C9HCN1 | |
| SCHEMBL4367214 | 0.78 | SLC6A9 (0.64) | SLC6A9CYP2C9 | |
| SCHEMBL678955 | 0.75 | SLC6A9 (0.82) | SLC6A9CYP2C9 | |
| SCHEMBL4719768 | 0.75 | SLC6A9 (0.67) | SLC6A9CYP2C9 | |
| SCHEMBL678461 | 0.75 | SLC6A9 (0.78) | SLC6A9CYP2C9 | |
| SCHEMBL4368884 | 0.75 | SLC6A9 (0.78) | SLC6A9CYP2C9 | |
| SCHEMBL3544127 | 0.74 | SLC6A9 (0.65) | SLC6A9CYP2C9 | |
| SCHEMBL3545064 | 0.74 | SLC6A9 (0.60) | SLC6A9CYP2C9 | |
| SCHEMBL3542503 | 0.74 | SLC6A9 (0.65) | SLC6A9CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1893566-B1 | CYCLOHEXANESULFONYL DERIVATIVES AS GLYT1 INHIBITORS TO TREAT SCHIZOPHRENIA | MERCK SHARP & DOHME (GB) | 2013-02-13 | — | — | EP | claimed |
| US-7626056-B2 | 2,4-Dichloro-N-(4-cyclopropylmethanesulfonyl-1-cyclopropylmethylcyclohexyl-methyl) benzamide; glutamatergic neurotransmission dysfunction and diseases; dementia; antidepressants; learning enhancement; cognition activators; attention deficit disorders; autism; eating disorders; anxiolytic agents | MERCK SHARP & DOHME LIMITED (GB) | 2009-12-01 | — | — | US | claimed |
| US-20060276655-A1 | Cyclohexanesulfonyl derivatives as GlyT1 inhibitors to treat schizophrenia | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2006-12-07 | — | — | US | claimed |
| EP-1893566-B1 | CYCLOHEXANESULFONYL DERIVATIVES AS GLYT1 INHIBITORS TO TREAT SCHIZOPHRENIA | MERCK SHARP & DOHME (GB) | 2013-02-13 | — | — | EP | disclosed |
| EP-1891002-B1 | CYCLOHEXANESULFONYL DERIVATIVES AS GLYT1 INHIBITORS TO TREAT SCHIZOPHRENIA | MERCK SHARP & DOHME (GB) | 2012-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276655-A1 | Cyclohexanesulfonyl derivatives as GlyT1 inhibitors to treat schizophrenia | GLRA1, GNMT, MGAT1 | SLC6A9 71/4885CYP2C9 1409/4885HCN1 994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.